drugset
drugset / Trial / NCT05068466

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of INCB054707

NCT05068466 ↗

Phase 1 Completed 30 enrolled Incyte Biosciences Japan GK
RandomizedParallel-groupDouble-blindTreatment

Summary

This is a single-center, randomized, double-blind, placebo-controlled, sponsor-unblinded, Phase 1 study designed to evaluate the safety, tolerability, and PK of escalating oral doses of INCB054707 in healthy male Japanese participants. Participants in each cohort will be divided into placebo or INCB054707 by a 3:1 INCB054707:placebo random assignment.

Timeline

Start
2021-10-21
Primary completion
2022-01-25
Completion
2022-01-25

Drugs

EvaluationDrugModalityDoseRoute
Subject Povorcitinib Small molecule — Oral

Indications

No indication recorded.